BPI 2026 · Large pharma

GSK at BPI 2026

London, United Kingdom

GSK brings 2 presentations to BPI 2026 in Boston. Its program centres on gene therapy manufacturing and facility readiness. One session presents a risk-tiered facility CQV strategy for qualification across the development-to-commercial continuum, aimed at getting sites ready faster.

OrganizationBPI 2026 Attendance
GSK
London, United Kingdom
1 Director, Quality Operations R & D
gsk.com
Large pharma
Global pharmaceutical company with marketed vaccines, specialty and general medicines.
Chair
Thu Sep 24
2:10pm–2:15pm
Chairperson’s Opening Remarks: Gene Therapy Manufacturing & Analytics
Gene Therapy Manufacturing & Analytics
Talk
Fri Sep 25
2:30pm–3:00pm
Accelerating Site Readiness: Risk-Tiered Facility CQV Strategy for Qualification from Development-to-Commercial Continuum
CMC Strategy & Manufacturing Performance

Explore the full BPI 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Boston. Leave your work email and we’ll be in touch.

Privacy

Download the full BPI 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from GSK

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by Informa Connect or the BioProcess International Conference & Exhibition. Submit a correction